Between Alcon, Sandoz, vaccines, and the OTC business, NVS now has a lot of moving parts, and it’s harder to decipher the company’s financial statements than it used to be.
Still, I think the company’s prospects are quite good relative to the stock’s valuation. The brouhaha re Gilenya will prove to be much ado about nothing, IMHO.
News 
Market Data 
Discover 
